Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Mar;17(3):295-304.
doi: 10.1038/gt.2009.148. Epub 2009 Nov 12.

Progress and prospects: immune responses to viral vectors

S Nayak  1 , R W Herzog
Affiliations
Review

Progress and prospects: immune responses to viral vectors

S Nayak et al. Gene Ther. 2010 Mar.

Erratum in

  • Gene Ther. 2010 Feb;17(2):294

Abstract

Viral vectors are potent gene delivery platforms used for the treatment of genetic and acquired diseases. However, just as viruses have evolved to infect cells efficiently, the immune system has evolved to fight off what it perceives as invading pathogens. Therefore, innate immunity and antigen-specific adaptive immune responses against vector-derived antigens reduce the efficacy and stability of in vivo gene transfer. In addition, a number of vectors are derived from parent viruses that humans encounter through natural infection, resulting in preexisting antibodies and possibly in memory responses against vector antigens. Similarly, antibody and T-cell responses may be directed against therapeutic gene products that often differ from the endogenous nonfunctional or absent protein that is being replaced. As details and mechanisms of such immune reactions are uncovered, novel strategies are being developed, and vectors are being specifically engineered to avoid, suppress or manipulate the response, ideally resulting in sustained expression and immune tolerance to the transgene product. This review provides a summary of our current knowledge of the interactions between the immune system adeno-associated virus, adenoviral and lentiviral vectors, and their transgene products.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: RWH has been receiving royalty payments from Genzyme Corp. for license of AAV-FIX technology.

Figures

Figure 1
Figure 1
Overview of immune responses to viral vectors. Targeting specific organs, engineering viral envelopes, switching serotypes, modifying the transgene cassette, utilizing tissue-specific promoters, or immune modulation regimens can result in immune avoidance to the viral vector and transgene product, and in some cases even induce tolerance to the therapeutic gene product.
Figure 2
Figure 2
Activation of complement by viral vector particles. AAV capsids bind to the C3 complement proteins C3, C3b, iC3b and complement regulatory factor H, hence increasing the uptake of virus into macrophages and enhancing their activation. C3-AAV capsid interactions are direct and can therefore occur independently of antibodies against capsid. However, the classical, antibody-dependent pathway also occurs. Similar interactions between Ad vector particles and complement have also been identified.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Waters B, Lillicrap D. The immunology of gene transfer: An overview. In: Herzog RW, editor. Gene Therapy Immunology. Wiley-Balckwell; Hoboken, NJ: 2009. pp. 1–18.
    1. Zaiss AK, Muruve DA. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther. 2008;15(11):808–16. - PubMed
    1. McCaffrey AP, Fawcett P, Nakai H, McCaffrey RL, Ehrhardt A, Pham TT, et al. The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver. Mol Ther. 2008;16(5):931–41. - PubMed
    1. Zhu J, Huang X, Yang Y. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest. 2009;119(8):2388–98. - PMC - PubMed
    1. Zaiss AK, Cotter MJ, White LR, Clark SA, Wong NC, Holers VM, et al. Complement is an essential component of the immune response to adeno-associated virus vectors. J Virol. 2008;82(6):2727–40. - PMC - PubMed

Publication types